Optical Genome Mapping as a Diagnostic Tool in Pediatric Acute Myeloid Leukemia

Abstract

Pediatric AML is characterized by numerous genetic aberrations (chromosomal translo-cations, deletions, insertions) impacting its classification for risk of treatment failure. Aberrations are described by classical cytogenetic procedures (karyotyping, FISH), which harbor limitations (low resolution, need for cell cultivation, cost‐intensiveness, experienced staff required). Optical Genome Mapping (OGM) is an emerging chip‐based DNA technique combining high resolution (~500 bp) with a relatively short turnaround time. Twenty‐four pediatric patients with AML, bi-lineage leukemia, and mixed‐phenotype acute leukemia were analyzed by OGM, and the results were compared with cytogenetics. Results were discrepant in 17/24 (70%) cases, including 32 previously unknown alterations called by OGM only. One newly detected deletion and two transloca-tions were validated by primer walking, breakpoint‐spanning PCR, and DNA sequencing. As an added benefit, in two cases, OGM identified a new minimal residual disease (MRD) marker. Com-paring impact on risk stratification in de novo AML, 19/20 (95%) cases had concordant results while only OGM unraveled another high‐risk aberration. Thus, OGM considerably expands the method-ological spectrum to optimize the diagnosis of pediatric AML via the identification of new aberra-tions. Results will contribute to a better understanding of leukemogenesis in pediatric AML. In ad-dition, aberrations identified by OGM may provide markers for MRD monitoring.